Multiple Myeloma News
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Source: Myeloma : nature.com subject feeds Post Content Read More
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Source: Myeloma : nature.com subject feeds Post Content Read More
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Elotuzumab Efficacy May Suffer if Given After Daratumumab in Multiple Myeloma
Source: Myeloma - Hematology Advisor Overall survival (OS) and other efficacy outcomes were worse among patients with multiple myeloma (MM) treated with elotuzumab-based regimens after having received daratumumab compared with patients who did not have prior...
Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma
Source: Pharmacy Times articles Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving...
Single Question Can Predict Treatment Discontinuation in MM Patients
Source: Myeloma - Hematology Advisor A single question can be used to predict early treatment discontinuation in patients with multiple myeloma (MM), according to research published in JAMA Network Open. Researchers found that a patient’s response to item 5 from the...
TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors
Source: Myeloma : nature.com subject feeds Post Content Read More
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Source: Myeloma : nature.com subject feeds Post Content Read More
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Source: Myeloma : nature.com subject feeds Post Content Read More
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
Source: Myeloma : nature.com subject feeds Post Content Read More